Chroma Therapeutics is focused on the discovery and development of a new generation of targeted small molecule treatments for cancer and inflammatory disorders. Chroma focuses on the inhibition of chromatin modifying enzymes (CMEs), which affect multiple aspects of tumor progression. The company’s strategy is to build a strong pipeline of first-in-class or best-in-class small molecule approaches against all key validated chromatin-related targets.